The immediate capital raise after earnings suggests underlying concerns about funding needs despite improved cash position. Monitor for potential delays in trial timelines or additional financing needs beyond current runway.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 17 $15.23entry
- T+1 · 7mo ago +1.12%α +1.31% · $15.40
- T+5 · 7mo ago −5.38%α −5.94% · $14.41
- T+20 · 6mo ago −0.98%α −6.36% · $15.08
- T+60 · 4mo ago +17.60%α +11.45% · $17.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics priced a $150 million follow-on offering just one day after reporting earnings, raising concerns about capital needs despite improved cash runway. The company provided updates on its Phase 3 trials for Haduvio, with topline results expected in 2027-2028.
Key Financial Metrics
Key Facts
- Priced $150 million follow-on offering at $13.00/share, one day after earnings report
- Cash runway extended to 2029 from $171.8 million as of March 31, 2026
- Net proceeds estimated at $141.1 million after fees
- Company maintains it will fund development through FDA approval for IPF indication
- No commercial expenses included in current cash runway estimates
Financial Impact
$150 million capital raise at $13.00/share with 13.8% discount to prior day's close
Risk Factors
- Dilution from 13.8% discounted offering
- Insufficient funds for commercial launch or development beyond IPF indication
- Potential trial delays if additional financing is needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-160355 |
| Document: d587027d8k.htm | 0001193125-26-160355 |
| Document: d587027dex991.htm | 0001193125-26-160355 |
| Document: d587027dex51.htm | 0001193125-26-160355 |
| Document: 0001193125-26-160355-index-headers.html | 0001193125-26-160355 |
| Document: 0001193125-26-160355-index.html | 0001193125-26-160355 |
| Document: 0001193125-26-160355.txt | 0001193125-26-160355 |
| 8-K Data (Synthetic) | 0001193125-26-160355 |
Track record
12 reports on TRVI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Viewing Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers